Bristol Myers' Opdivo steps in FDA fast lane for potential first-in-class nod in pre-surgery lung cancer

28th February 2022 Uncategorised 0

Bristol Myers’ Opdivo steps in FDA fast lane for potential first-in-class nod in pre-surgery lung cancer
aliu
Mon, 02/28/2022 – 09:10

More: Bristol Myers' Opdivo steps in FDA fast lane for potential first-in-class nod in pre-surgery lung cancer
Source: fierce